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PROGNOSTIC  VALUE  OF ADMISSION  GLUCOSE  
AND  GLYCOSYLATED  HAEMOGLOBIN  LEVELS  IN 
ACUTE ST ELEVATION MYOCARDIAL INFARCTION                                                                        
                                                                 ABSTRACT 
 
BACKGROUND: Coronary heart disease is common in people with diabetes 
mellitus. Diabetes is associated with a poor prognosis in patients with an acute 
coronary syndrome (ACS), either with or without ST-elevation (STEMI/non-
STEMI). However, more acute glycometabolic disturbances may also have a 
negative impact on outcome. Elevated glucose levels on admission are associated 
with increased mortality after ACS, irrespective of diabetic status. Whether 
HbA1c levels have the same prognostic significance as glucose levels in an 
emergency setting is unknown. 
AIM: To investigate the prognostic value of admission glucose and glycosylated 
hemoglobin levels in acute ST elevation myocardial infarction and to assess the 
importance of long term blood glucose control as reflected by HbA1c in predicting 
outcome after acute ST elevation myocardial infarction. 
METHODS: This was a prospective observational study conducted on 80 patients 
admitted to the Cardiology ICCU ward at Government Rajaji Hospital, Madurai 
with acute ST elevation myocardial infarction, irrespective of their previous 
diabetic status. We measured blood glucose and Hba1c at admission in these 
patients. The 80 patients included in this study were further stratified into five 
groups, based on previous history of diabetes, blood glucose levels at admission 
and HbA1c levels. Group 1(uncontrolled diabetes) included patients with previous 
history of diabetes with HbA1c > 6.5 %.Group 2(controlled diabetes) included 
those with previous history of diabetes with HbA1c ≤ 6.5 %.Group 3 (stress 
hyperglycemia) was patients with no previous history of diabetes, random blood 
glucose at admission ≥ 200 mg/dl and HbA1c < 6.5 %.Group 4 (undiagnosed 
diabetes)included those with no previous history of diabetes, random blood glucose 
≥ 200 mg/dl and HbA1c ≥ 6.5%.Group 5(nondiabetic) included those with no 
previous history of diabetes, random blood glucose < 200 mg/dl and HbA1c < 6.5 
%.These patients were followed up during the hospital stay and complication rates  
were assessed. 
RESULTS : There were 27 subjects under group 1 (uncontrolled diabetes) of 
which 70.4 % had complications during hospital stay and 66.7 % had a left 
ventricular ejection fraction(LVEF) ≤ 40 %.Among the 5 patients in group 2 
(controlled diabetes),only 1 developed complication during hospital stay and all 
had an LVEF > 40 %.In group 3 (stress hyperglycemia),both patients developed 
complications and had an LVEF ≤ 40 %.There were 9 subjects in group 4 
(undiagnosed diabetes),out of which 66.7 % developed complications and all had 
an LVEF ≤ 40 %.Group 5 included 37 patients, out of which only 8.1 % developed 
complications and only 13.5 % had an LVEF ≤ 40 %. Moreover, there was a 
significant negative correlation between HbA1c levels and left ventricular ejection 
fraction. There was also a significant negative correlation between admission blood 
glucose levels and left ventricular ejection fraction. 
DISCUSSION: Our results suggest that both acute and chronic hyperglycemia are 
independent predictors of adverse outcome after acute ST elevation myocardial 
infarction. Hence, measurement of both blood glucose as well as HbA1c enables 








The global prevalence of diabetes mellitus has been estimated to 
be at 170 million individuals and is rapidly increasing with projections 
of > 350 million by 2030.Coronary heart disease is common in people 
with diabetes mellitus. The presence of elevated blood glucose levels, 
diabetes mellitus, or both contribute to more than 3 million 
cardiovascular deaths worldwide each year. Diabetes is associated with 
a poor prognosis in patients with an acute coronary syndrome (ACS), 
either with or without ST-elevation (STEMI/non-STEMI). 
1–3
 However, 
more acute glycometabolic disturbances may also have a negative 
impact on outcome. Elevated glucose levels on admission are associated 
with increased mortality after ACS, irrespective of diabetic status. 
4–
8
 Recent evidence has shown that chronic glucose dysregulation, as 
assessed by glycosylated hemoglobin (HbA1c) levels, may also be of 





 Whether HbA1c levels have the same prognostic 
significance as glucose levels in an emergency setting is unknown. This 
study was undertaken to investigate the independent prognostic value of 
HbA1c levels and admission glucose in patients with acute ST elevation 
myocardial infarction, irrespective of their diabetic status. 
  
CORONARY ARTERY DISEASE: 
The term “Acute Coronary Syndrome” (ACS) refers to a range of 
acute myocardial ischemic states which include unstable angina, non ST 
elevation myocardial infarction (NSTEMI), and ST segment elevation 
myocardial infarction (STEMI).Despite significant advances in the 
diagnosis and management, ACS remains a significant global problem 
with very high mortality and morbidity. The pathogenetic process 
central to the initiation of an ACS is disruption /fissuring of an 
atheromatous plaque and consequent exposure of core constituents such 
as lipid, smooth muscle, and foam cells, leading to the local generation 
of thrombin and deposition of fibrin. This in turn promotes platelet 
aggregation and adhesion and the formation of intracoronary 
thrombus
11
. STEMI continues to be a significant public health problem 
in industrialized countries and is becoming an increasingly significant 




   A recent expert consensus document redefined acute MI as the 
detection of a rise and /or fall in cardiac biomarkers with at least one 
value above the 99
th
 percentile of the upper reference limit (URL), 
together with evidence of ischemia. Ischemia was defined as any 
  
symptoms of ischemia (chest pain, breathlessness, syncope, confusional 
state, arrhythmias), electrocardiographic changes suggestive of new 
ischemia, development of pathologic Q waves on electrocardiogram 
(ECG) or imaging evidence of infarction. Included in the definition was 
sudden cardiac death with evidence of myocardial ischemia (new ST 
elevation, left bundle branch block, or coronary thrombus), biomarker 
elevation >3×URL for post PCI patients, or >5 ×URL for post coronary 
artery bypass grafting (post-CABG) patients. Documented stent 
thrombosis was recognized in this new definition as well. Established 
MI was defined as any one criterion that satisfies the following: 
development of new pathologic Q waves on serial ECGs, imaging 




The pathophysiologic hallmark of ACS is that of: 
1)  A fissured atherosclerotic plaque with a platelet rich thrombus 
which is subtotally/completely occlusive, often over mild to 
moderately stenotic lesions along with 
2)  Impaired distal circulation due to micro embolisation from the 
plaque disruption. 
3) Other causative/perpetuating mechanisms: vasospasm. 
  
The eventual outcome (UA / NSTEMI / STEMI / Sudden cardiac 
death) depends upon the anatomical location of the lesion, extent of 
plaque disruption and duration & type of occlusion. Coronary 
angiogram early in STEMI reveals complete occlusion of the culprit 
artery in around 90% of patients. However, in NSTE-ACS, the culprit 
vessel is not occluded in 60-85% of patients. In STEMI, the complete 
occlusion of an epicardial coronary artery occurs due to fibrin rather 
than platelet rich thrombus. The thrombotic mechanisms have an impact 
on the way these syndromes are treated, both in the coronary care & 
catheter laboratory setting. 
VULNERABLE PLAQUE: 
Basically, plaque formation in human coronary arteries could start 
as early as second decade. A coronary plaque consists of a lipid core 
surrounded by a fibrous cap. With age, a stable plaque may progress 
without major disruption & cause no symptoms or stable angina. The 
relative thickness & consistency of the lipid & the fibrous core 
determines the propensity of the plaque to rupture. Also, there is plenty 
of evidence now from studies which show that the inflammatory cascade 
is at the heart of the plaque rupture, responsible for initiation & 
sustenance of the effects which result in a subclinical or frank ACS.  
  





Altered / reduced collagen support combined with inflammatory 
activity makes the plaque highly vulnerable. 
The larger the lipid core & the thinner the fibrous cap, the more 
vulnerable is the atheroma to rupture. The basic mechanisms involved in 
plaque rupture are: 
 Problems with collagen in the fibrous cap 
 Various triggers, including mechanical stress 
 Sympathetic stimulation 
 Inflammation 
Collagen cap problems: Interstitial collagen is the main constituent of 
the fibrous cap layer of the plaque & is formed by the smooth muscle 
cells. Three mechanisms may affect this aspect of the plaque: a) 
impaired collagen formation by smooth muscle cells, b) breakdown of 
smooth muscle cells & c) collagen breakdown by various enzymes 
(collagenases, matrix metalloproteinase) secreted preferentially in the 
vulnerable regions of the plaque. Dysfunctional collagen impairs the 
ability of the plaque to remain stable & with the right trigger(s), the cap 
of the plaque gives away, commonly at the “shoulder regions”(areas of 
junction between a normal segment of the artery & the atheroma).This 
exposes the endothelial basement membrane & the central lipid core of 
  
the atheroma(both of which being highly thrombogenic structures)to the 
circulating blood components, initiating the platelet  & coagulation 
cascade &eventually causing micro/macro thrombosis with/without 
symptoms/events. 
In STEMI, after an initial platelet monolayer forms at the site of the 
disrupted plaque, various agonists (collagen, ADP, epinephrine, 
serotonin) promote platelet activation. After agonist stimulation of 
platelets, thromboxane A2 (a potent local vasoconstrictor) is released, 
further platelet activation occurs and potential resistance to fibrinolysis 
develops. In addition to the generation of thromboxane A2, activation of 
platelets by agonists promotes a conformational change in the 
glycoprotein IIb / IIIa receptor. Once converted to its functional state, 
this receptor develops a high affinity for amino acid sequence on soluble 
adhesive proteins (i.e., integrins) such as fibrinogen. Since fibrinogen is 
a multivalent molecule, it can bind to two different platelets 
simultaneously, resulting in platelet cross-linking and aggregation. The 
coagulation cascade is activated on exposure of tissue factor in damaged 
endothelial cells at the site of the disrupted plaque. Factors VII and X 
are activated, ultimately leading to the conversion of prothrombin to 
thrombin, which then converts fibrinogen to fibrin. Fluid-phase and clot-
  
bound thrombin participate in an auto amplification reaction leading to 
further activation of the coagulation cascade. The culprit coronary artery 
eventually becomes occluded by a thrombus containing platelet 
aggregates and fibrin strands. 
Triggers for ACS: 
Increased sympathetic stimulation is well known to cause ACS & 
the underlying mechanism could include rise in heart rate & the blood 
pressure which increase plaque “stress” & increase thrombogenicity by 
stimulating platelet activity. This has been thought to be the basis of 
increased incidence of ACS in the early morning hours due to 
heightened sympathetic surge. Also, in predisposed individuals, exercise 
or emotional stress might cause plaque rupture due to catecholaminergic 
surge leading to increased wall stress. Other mechanisms also include 
vasospasm, mechanical effects due to rapid, increased flexing of 
coronary arteries(at the bend points on the epicardium). Exercise may 
also lead to deepening of the already existing plaque fissures & cause 
enhanced platelet aggregation. Mechanical stress on the morphologically 
vulnerable plaques makes them more prone to rupture. The flow 
dynamics of the coronary artery determine the level of mechanical strain 
experienced by the coronary atheroma.Circumferential, radial & 
  
longitudinal deformation of the plaque contribute to the processes of 
inflammation, erosion, destabilization, fatigue of the cap area of the 
plaque and eventually plaque rupture and thrombosis. The disruption in 
the integrity of the plaque could occur superficially or as a deep rupture. 
Role of inflammation: 
There is a strong association between plaque inflammation and 
rupture. Compared to a stable plaque, an unstable & disrupted plaque 
displays significantly high inflammatory activity. Secretion of 
inflammatory markers like interleukins & gamma interferon play a vital 
role in perpetuating the process. Past studies have also found increased 
inflammatory potential of oxidized lipoproteins in the regions of 
coronary atheroma. Inflammation with its cytotoxic effects degrades the 
collagen layer & helps to aggravate plaque vulnerability by making it 
more prone to disruption & eventually thrombosis. 
CLINICAL FEATURES: 
The cardinal symptom is the ischemic chest pain which is 
typically described by the patient as burning, tightness or heaviness. 
Patients with STEMI usually have severe chest pain with fear of dying, 
whereas in non-ST elevation ACS the pain is more waxing and waning, 
is dependent on the level of exertion, but usually lasts no longer than 20 
  
minutes. The pain is typically located in the centre or the left lateral 
chest and radiates to the left shoulder, arm, neck and jaw. Pain may also 
be epigastric ,particularly in inferior wall MI. Perception of pain in the 
right side of the chest does not exclude myocardial ischemia. However, 
pain is not uniformly present in patients with STEMI. The proportion of 
painless STEMI is greater in diabetics and it increases with age. In the 
elderly, it may present as sudden onset breathlessness, which may 
progress to pulmonary edema. Other less common presentations, with or 
without pain, include sudden loss of consciousness, a confusional state, 
a sensation of profound weakness, the appearance of an arrhythmia, 
evidence of pulmonary embolism or merely an unexplained drop in 
arterial pressure. 
PHYSICAL EXAMINATION: 
The major purpose of the examination is to exclude non cardiac 
causes of chest pain, non ischemic cardiac disorders (eg.pericarditis, 
valvular disease), potential precipitating extra cardiac causes, 
pneumothorax, and to look for signs of potential hemodynamic stability 
and left ventricular dysfunction. The combination of substernal chest 
pain persisting for >30 min and diaphoresis strongly suggests STEMI. 
The precordium is usually quiet and the apical impulse may be difficult 
  
to palpate. In patients with anterior wall infarction, an abnormal systolic 
pulsation caused by dyskinetic bulging of infarcted myocardium may 
develop in the periapical area within the first days of the illness and then 
may resolve. Other physical signs of ventricular dysfunction include 
fourth and third heart sounds, decreased intensity of the first heart sound 
and paradoxical splitting of the second sound. A transient midsystolic or 
late systolic apical systolic murmur due to dysfunction of the mitral 
valve apparatus may be present. A pericardial friction rub is heard in 
many patients with transmural STEMI at some time in the course of the 
disease. The carotid pulse is often decreased in volume, reflecting stroke 
volume. Temperature elevations upto 38⁰C may be observed during the 
first week after STEMI.The arterial pressure is variable; in most patients 
with transmural infarction, systolic pressure declines by approximately 
10-15mm Hg from the preinfarction state. 
LABORATORY FINDINGS: 
The laboratory tests can be divided into: 
1) Electrocardiogram 
2) Serum cardiac biomarkers 
3) Cardiac imaging 
4) Nonspecific indices of tissue necrosis & inflammation. 
  
ELECTROCARDIOGRAM: 
The ECG remains an important screening tool and it may also 
provide evidence of alternative diagnosis such as pericarditis, 
pulmonary embolism, or cardiomyopathy. 
Definite electrocardiographic evidence of acute MI requires ST 
elevation of 1mm or more in two or more contiguous leads, often with 
reciprocal ST depression in the contra lateral leads. In leads V2 – V3, 2 
mm of ST elevation in men and 1.5mm in women is required for 
accurate diagnosis. 
New LBBB in the setting of symptoms of acute MI may indicate 
a large, anterior wall acute MI involving the proximal left anterior 
descending coronary artery and should be managed as acute MI.Right 
bundle branch block complicates interpretation of ST elevation in leads 
V1-V3.The diagnosis of anterior acute MI is possible when the normal 
secondary T wave changes in a patient with RBBB in leads V1-V4 are 
replaced with T waves of concordant polarity with the QRS(i.e. 





   
 
 








CKMB ++ + 4h 24h 72h 
MYOGLOBIN + + 2h 6-8h 24h 
TROPONIN T +++ +++ 4h 24-48h 5-21days 
TROPONIN I +++ +++ 3-4 h 24-36h 5-14days 
 
 
MARKER ADVANTAGES DISADVANTAGES 
CK - MB Rapid  
Cost effective 
Detected early in infarctions 
Loss of specificity with skeletal 
muscle damage 
Detection after 6 hours of 
myocardial necrosis 
Myoglobin Highly sensitive 
Early detection of MI within 2 
hours 
Detects reperfusion 
Most useful in ruling out MI 
Low specificity with skeletal 
muscle damage 
Rapid return to normal 
Troponins Powerful tool for risk stratification 
Greater sensitivity and specificity 
than CK – MB 
Detects recent MI upto 2 weeks 
Helpful to determine therapy 
Detection of reperfusion 
Low sensitivity in MI of less than 
6 hours 
Require repeat measures at 8 -12 
hours if first result is negative 
Less able to detect late, minor MIs 
  
CARDIAC IMAGING: 
ECHOCARDIOGRAPHY: Left ventricular systolic function is an 
important prognostic variable in patients with ACS and can be easily 
and accurately be assessed by echocardiography. Regional wall motion 
abnormalities occur within seconds after coronary occlusion well before 
necrosis. However, these are not specific for acute events and maybe the 
result of old infarctions. Transient localized hypokinesia or akinesia in 
segments of the left ventricle may be detected during ischemia, with 
normal wall motion on resolution of ischemia. The absence of wall 
motion abnormalities excludes major myocardial infarction. 
 
CORONARY ANGIOGRAPHY: 
This is the gold standard to prove or exclude coronary artery 
disease. The extent and location of lesions is useful for risk assessment 
and decision making concerning revascularization by means of 
angioplasty or surgery. The culprit lesions that are responsible for the 
clinical symptoms, frequently show filling defects, indicating 
intracoronary thrombus formation. 
 
  
MYOCARDIAL PERFUSION SCINTIGRAPHY: 
A normal resting technetium 99 myocardial perfusion scintigram 
effectively excludes major myocardial infarction. An abnormal acute 
scintigram is not diagnostic of acute infarction unless it is known to be 
previously normal, but it does indicate the presence of coronary artery 
disease and the need for further evaluation. 
CARDIAC MAGNETIC RESONANCE IMAGING: 
The multimodality characteristic of cardiac MRI provides a 
comprehensive examination, combining regional contractile function, 
myocardial perfusion and viability. In addition, it can also rule out other 
potential reasons for the chest pain. 
CT ANGIOGRAPHY: 
It has a high negative predictive value meaning that if it is normal 
then there is a high likelihood that the patient is not having coronary 
heart disease but if CT angiography is showing stenosis in the coronary 
arteries that it is quite possible that it may be a false positive 
result.Hence, this test is useful for evaluating patients with a low 
probability of CAD. 
 
  
RISK STRATIFICATION:  
Five simple baseline parameters have been reported to account for 
more than 90% of the prognostic information for 30 day mortality. 
These are age, systolic blood pressure, Killip classification, heart rate, 
and location of MI. 
30-DAY MORTALITY BASED ON HEMODYNAMIC  
(KILLIP) CLASS: 
KILLIP CLASS CHARACTERISTICS MORTALITY (%) 
I No evidence of CHF 5.1 
II Rales,↑JVP or S3 13.6 
III Pulmonary edema 32.2 
IV Cardiogenic shock 57.8 
 
TREATMENT: 
1)  IMMEDIATE MANAGEMENT AND STABILISATION: 
a) ASPIRIN: Immediate administration of aspirin is indicated for all 
patients with acute MI,unless there is a clear history of true aspirin 
allergy(not intolerance).The  dose should be four, chewable 81mg 
tablets(for more rapid absorption)or one 325 mg nonchewable tablet. If 
oral administration is not possible, a rectal suppository can be given. 
  
b)  THIENOPYRIDINES: Recent data indicate that clopidogrel 
should be added to aspirin in STEMI patients regardless of whether they 
undergo primary PCI or fibrinolysis.The CLARITY-TIMI 28 trial 
showed pretreatment with clopidogrel to be safe and effective without 
increased bleeding among patients treated with fibrinolytic therapy, with 
many receiving subsequent PCI.The COMMIT-CCS 2 trial found a 
significant reduction in all-cause mortality but no difference in major 
bleeding. An oral loading dose of 300 mg is given followed by 75 mg 
daily.  
c)  OXYGEN: Supplemental oxygen through nasal cannula should 
be given to all patients with suspected MI.Administration through face 
mask or endotracheal tube may be necessary for patients with severe 
pulmonary edema or cardiogenic shock. 
d)  NITROGLYCERIN: It is worthwhile to give sublingual 
nitroglycerin (0.4 mg) to determine whether the ST segment elevation 
represents coronary artery spasm while arrangements for reperfusion 
therapy are being initiated. Nitroglycerin can be useful in the 
management of acute MI complicated by CHF,ongoing symptoms or 
hypertension. 
  
e)  REPERFUSION THERAPY: Prompt and effective reperfusion 
therapy is the cornerstone of treatment for acute STEMI and is the only 
widely applicable acute treatment to diminish infarct size and major 
cardiac complications. The European guidelines for the management of 
acute MI recommend that for patients with clear cut changes of acute 
infarction ,no more than 20 minutes should elapse between hospital 
arrival and the administration of thrombolytic therapy (or prehospital 
administration) or no more than 60 minutes between hospital arrival and 




AGENTS CHARACTERISTICS DOSE TRIALS 
ALTEPLASE 
(tPA) 
Fibrin specific 15 mg bolus followed by 
0.75 mg/kg(upto 50 mg) 
over 30 min, then 
0.5mg/kg over 60 min 
GUSTO I (Global 
Utilization of Streptokinase 
and Tissue Plasminogen 
Activator for Occluded 
Coronary Arteries) 
RETEPLASE Less fibrin specific, 
longer half life 
Double bolus(10 mg each 




Fibrin specific, resistant 
to plasminogen 
activator inhibitor  
(PAI -1) 
Single bolus, 30 – 40 mg 
(ASSENT 1) 
ASSENT 2 (Assessment of 
the Safety and Efficacy of 





ment of antibodies 
1.5million units (7,50,000 
units over 20 minutes 
followed by 7,50,000 
units over 40 minutes) 
 
    
     
  




 Previous hemorrhagic stroke at any time; ischemic stroke within 3 
months 
 Known intracranial neoplasm, structural cerebral vascular lesion or 
closed head injury within 3 months 
 Active bleeding or bleeding diathesis (excluding menses) 
 Suspected aortic dissection 
Relative contraindications: 
 Severe, uncontrolled hypertension at presentation (blood pressure > 
180/110 mm Hg) or history of chronic severe hypertension 
 History of ischemic stroke>3 months,dementia,or known 
intracerebral pathologic conditions not covered in contraindications 
 Current use of anticoagulants, the risk increases with increasing INR 
 Traumatic or prolonged (>10 min)CPR or major surgery(<3 wks) 
 Noncompressible vascular punctures 
 Recent (within 2-4 wks) internal bleeding 
 For streptokinase :  prior exposure or prior allergic reaction 
 Pregnancy 
 Active peptic ulcer 
  
PRIMARY PCI: 
Individual trials comparing fibrinolytic therapy with primary PCI 
and the meta analysis of such trials have shown that primary PCI done 
promptly by an experienced team is superior to fibrinolytic therapy in 
centres with a high volume of PCI procedures
15
.Primary PCI is the 
preferred strategy for patients with acute ST elevation MI if, with 
appropriate facilities, a skilled team can provide PCI within 60 minutes 
of hospital arrival. 
FACILITATED PCI: 
Facilitated PCI may offer advantages but larger scale trials are 
awaited. The CAPITAL AMI trial compared fibrinolytic therapy with 
Tenecteplase (TNK) alone versus TNK –facilitated PCI in high risk 
STEMI patients. The primary composite end points of death, 
reinfarction, recurrent unstable angina, or stroke at 6 months were 
24.4% in TNK arm and 11.5% in facilitated PCI arm. 
PCI COMBINED WITH Gp IIb/IIIa inhibitors: 
The combination of Gp IIb / IIIa inhibitors and primary PCI has 
been tested in several studies (RAPPORT, ISAR 2, CADILLAC, 
ADMIRAL, and ACE Trials).The pooled analysis suggests that Gp 
  
IIb/IIIa inhibition reduces adverse outcomes (death/MI and target vessel 
revascularization) in primary PCI (without a lytic agent).Thus for 
primary PCI, addition of Gp IIb/IIIa inhibitor (abciximab) may be 




Rescue PCI refers to a PCI procedure performed in patients 
without evidence of a response to thrombolysis (<50% ST segment 
resolution) and feasibility studies have demonstrated success of PCI in 
achieving coronary patency and flow.However,insufficient data are 
available to demonstrate whether there is improvement in mortality or 
further MI.  
ROLE OF HEPARIN: 
As an adjunct to tPA, heparin has been shown to improve late 
patency. The dose of heparin recommended by the AHA/ACC 
guidelines is 60U/kg bolus(maximum,4000 units) followed by 
12U/kg/hr (maximum 1000 U/hr). 
OTHER DRUGS: 
Beta blockers: The TIMI IIb trial compared immediate intravenous 
Metoprolol (within 6 hrs of onset of chest pain )to delayed oral 
  
metoprolol(on day 6).Early intravenous treatment was associated with 
significant reduction in 6 week mortality or reinfarction.ISIS 1 study 
also confirmed the mortality benefits of early beta-blocker therapy. 
ACE inhibitors: A series of trials (SAVE, AIRE, SMILE, TRACE, 
GISI III, and ISIS-4) have shown both short term and long term 
improvement in survival after ACE inhibitor therapy. The benefits are 
greatest in patients with low ejection fraction, large infarctions or 
clinical evidence of heart failure. Because substantial amounts of the 
survival benefit occur on the first day, ACE inhibitor treatment should 
be commenced early in patients without hypotension, especially patients 




ACUTE CORONARY SYNDROME AND DIABETES 
MELLITUS: 
In India, there is a joint epidemic of type 2 diabetes and Coronary 
Artery Disease (CAD)
17
.Epidemiological studies in urban and rural 
population performed over the last 50 yrs have clearly shown an 
increase in the prevalence of diabetes as well as CAD in rural and urban 
population. The prevalence of type2 diabetes has increased from less 
than 1% in rural and 1.5 in urban areas in 1960‟s to 6-8% in rural and 
10-15% in urban population currently
18
.The prevalence of CAD has 
increased from less than 1% in rural populations to 4-5 % presently, and 
in urban location from 1-2% in 1960‟s to 9-12% presently18.Diabetes is 
now considered a cardiovascular disease equivalent by the UN National 
Cholesterol Education Program Guidelines. Hyperinsulinemia and 
insulin resistance, the hallmark abnormalities in diabetes mellitus,cause 















Multiple hypothesis exist to explain the occurrence of premature 
atherosclerosis in diabetes in India but the consensus is that it is 
multifactorial.Important factors include dyslipidemia, hypertension, 
hypercoagulability, poor glycemic control, smoking, obesity and lack of 
physical activity. Of these, the factors that appear mechanistically most 
important are 
1. Hyperglycemia affecting the vessel wall 
2. Diabetic dyslipidemia 
3. Hyperglycemia versus dyslipidemia 
4. Chronic subclinical inflammation in the vessel wall19. 
↑ PAI – 1 (Plasminogen 
activated inhibitor – 1) 















Results of basic studies in vitro, in animal models, and in patients 
with diabetes mellitus suggest several mechanisms by which 
hyperglycemia might affect atherogenesis at the level of the arterial 
wall
24,25
.Firstly,high glucose concentrations can activate nuclear factor 
kB(NF-kB),which in turn can increase the expression of various genes 
in the endothelial cells,monocyte derived macrophages, and vascular 
smooth muscle cells.Secondly,advance glycation end-products(AGEs) 
including protein crosslinks,fluorophors and other low molecular weight 
residues are formed by sustained exposure of proteins and lipids to high 
concentrations of glucose, which can generate reactive oxygen species, 
ligation of AGEs to specific cell-surface receptors can regulate gene 
expression in vessel wall cells. Thirdly, glucose also increases oxidative 
stress, which has several possible harmful effects on the artery wall, e.g., 
auto-oxidation of glucose leads to the formation of several reactive 
oxygen species, such as the superoxide anion, which can promote 
oxidation in vitro. And fourthly, indirect observational evidence 
suggests that lipoprotein oxidation might be increased in patients with 
type 2 diabetes and is related to glycemic control. On the other hand, 
absence of highly specific markers in collagen, plasma, or urine from 
individuals with diabetes does not support a generalized increase in 




CLINICAL TRIALS IN TYPE 2 DIABETES AND ACS : 
1) The Action to Control Cardiovascular Risk in Diabetes 
(ACCORD) study was a randomized controlled study designed to 
determine whether normal HbA1c levels would reduce the risk of 
cardiovascular events in middle-aged or older individuals with type 2 
diabetes. About 35% of the 10,251 recruited subjects had established 
cardiovascular disease at study entry. The intensive arm of the study was 
discontinued after 3.5 years of follow-up because of more unexplained 
deaths in the intensive arm when compared with the control arm (22%, 
P = 0.020). Analysis of the data at time of discontinuation showed that 
the intensively treated group (mean HbA1c 6.4%) had a 10% reduction in 
cardiovascular event rate compared with the standard treated group 




2) The Action in Diabetes and Vascular disease : Preterax and 
Diamicron MR Controlled Evaluation (ADVANCE) trial randomly 
assigned 11,140 patients with type 2 diabetes to standard or intensive 
glucose control. The primary outcomes were major macrovascular 
cardiovascular events (nonfatal myocardial infarction or stroke or death 
from cardiovascular causes) or microvascular events. Overall, one-third 
  
(32%) of the subjects had established cardiovascular disease at study 
entry. After a median follow-up of 5 years, there was a nonsignificant 
reduction (6%) in major macrovascular event rate in the intensively 




3) The Veteran Administration Diabetes Trial (VADT) randomly 
assigned 1791 patients from age 50 to 69 years with type 2 diabetes to 
standard or intensive glucose control. Overall, 97% of the subjects were 
men. The primary outcome was a composite of myocardial infarction, 
death from cardiovascular causes, congestive heart failure, vascular 
surgery, inoperable coronary artery disease, and amputation for 
gangrene. All the patients had optimized blood pressure and lipid levels. 
After a median follow-up of 5.6 years, there was no significant 
difference in the primary outcome in the intensively treated group 
(HbA1c 6.9%) compared with the standard therapy (HbA1c 8.4%)
22
.  
Thus, the ACCORD, ADVANCE, and VADT results do not 
provide support for the hypothesis that near-normal glucose control in 
patients with type 2 diabetes will reduce cardiovascular events. It is, 
however, important not to over-interpret the results of these three 
studies. The results do not exclude the possibility that cardiovascular 
  
benefits might accrue with longer duration of near-normal glucose 
control. The ACCORD, ADVANCE, and VADT studies recruited 
patients who had diabetes for 8–10 years and one-third of them already 
had established cardiovascular disease. A large meta-analysis of 
multiple studies recently reported effectiveness of tight glycemic control 
for cardiovascular risk reduction and concluded that optimum measures 
to achieve this need to be established
23
.  
4) The  Diabetes Mellitus Insulin-Glucose Infusion in Acute 
Myocardial Infarction – 1 (DIGAMI – 1) study compared "conventional" 
anti-diabetic therapy to intensive insulin therapy consisting of acute 
insulin infusion during the early hours of MI and thrice-daily 
subcutaneous insulin injection for the remainder of the hospital stay and 
a minimum of 3 months thereafter.  Glucose control improved and long-
term mortality decreased 30% to 50% for persons not previously 
receiving insulin, with decreased mortality of subsequent myocardial 
infarction, while the control group with type 2 diabetes had 35% to 40% 
overall mortality after several years. Furthermore, A1C decreased by 
0.9% in the intervention group - by 1.5% among patients who had not 
previously received insulin. Although there was an overall reduction in 
adverse outcomes in patients receiving the intensive insulin regimen, it 
  
is unclear which component (the IV insulin infusion or the intensive 
chronic therapy) was responsible.  
5) The DIGAMI 2 study was an international (48-center) trial 
involving 3000 subjects with a trial design similar to that of DIGAMI 1, 
enrolling persons with known diabetes or with initial glucose > 11 
mM/L (198 mg/dL) presenting with acute myocardial infarction with 
duration of symptoms < 24 hours. Study participants were randomized 
to 1 of 3 groups. Patients in the first group had a glucose/insulin 
infusion for at least 24 hours and then were treated with subcutaneous 
(SC) insulin. The second intervention group was treated acutely with 
glucose/insulin infusion for at least 24 hours and then returned to 
conventional treatment. The third intervention group received 
conventional treatment only. Sample size calculations were based on the 
projection that there would be 30% mortality in the control group and 
mortality rates of 17% and 23% in groups 1 and 2, with stratification 
based on cardiovascular risk and prior insulin treatment. 
The study, however, was closed on May 21, 2003, because of a 
slow recruitment rate and only minor differences in long-term A1C 




6)  The United Kingdom Prospective Diabetes Study (UKPDS) : 
This multicenter study was designed to establish, in type 2 diabetic 
patients, whether the risk of macrovascular or microvascular 
complications could be reduced by intensive blood glucose control 
with oral hypoglycemic agents or insulin and whether any 
particular therapy was of advantage. A total of 3867 patients aged 
25–65 years with newly diagnosed diabetes were recruited between 
1977 and 1991, and studied over 10 years. The median age at 
baseline was 54 years; 44% were overweight (> 120% over ideal 
weight); and baseline HbA1c was 9.1%. Therapies were randomized 
to include a control group on diet alone and separate groups 
intensively treated with either insulin or sulfonylurea 
(chlorpropamide, glyburide, or glipizide). Metformin was included 
as a randomization option in a subgroup of 342 overweight or 
obese patients, and much later in the study an additional subgroup 
of both normal-weight and overweight patients who were 
responding unsatisfactorily to sulfonylurea therapy were 
randomized to either continue on their sulfonylurea therapy alone 
or to have metformin combined with it.  
  
Intensive treatment with either sulfonylureas, metformin, 
combinations of those two, or insulin achieved mean HbA1c levels 
of 7%.No cardiovascular benefit and no adverse cardiovascular 
outcomes were noted regardless of the therapeutic agent. 
Hypoglycemic reactions occurred in the intensive treatment groups, 
but only one death from hypoglycemia was documented during 
27,000 patient-years of intensive therapy. 
However, the UKPDS researchers performed post-trial 
monitoring to determine whether there were long-term benefits of 
having been in the intensively treated glucose arm of the study. 
The between-group differences in HbA1c were lost within the 
first year of follow-up, but the reduced risk (24%, P = 0.001) of 
development or progression of microvascular complications in the 
intensively treated group persisted for 10 years. The intensively 
treated group also had significantly reduced risk of myocardial 
infarction (15%, P = 0.01) and death from any cause (13%, P = 
0.007) during the follow-up period. The subgroup of overweight or 
obese subjects who were initially randomized to metformin therapy 
  
showed sustained reduction in risk of myocardial infarction and 
death from any cause in the follow-up period. 
Thus, the follow-up of the UKPDS type 2 diabetes cohort 
showed that the benefits of good glucose control persist even if 
control deteriorates at a later date. 
It appears that glycemic control to levels of HbA1c to 7% 
shows benefit in reducing total diabetes end points, including a 
25% reduction in microvascular disease as compared with HbA1c 
levels of 7.9%. This reassures those who have questioned whether 
the value of intensive therapy, so convincingly shown by the DCCT 
in type 1 diabetes, can safely be extrapolated to older patients with 
type 2 diabetes. It also argues against the concept of a "threshold" 
of glycemic control since in this group there was a benefit from this 
modest reduction of HbA1c below 7.9% whereas in the DCCT ( 
Diabetes Control and Complications Trial ) a threshold was 




CLINICAL OUTCOMES IN ACS: 
Mortality and reinfarction rate are substantially increased in 
diabetic patients following myocardial infarction. In general, there is an 
increased mortality across the spectrum of acute coronary syndromes, 
with increased mortality rate at 30 days for patients with and without ST 
elevation (combined non-ST segment elevation infarction and unstable 
angina).One of the very interesting findings in the study by McGuire et 
al. is a grossly increased rate of reinfarction in diabetic patients without 













AIM OF THE STUDY 
1)  To investigate the prognostic value of admission glucose and 
glycosylated hemoglobin levels in acute ST elevation 
myocardial infarction. 
2)  To assess the importance of long term blood glucose control 
as reflected by HbA1c in predicting outcome after acute ST 











                                      METHODOLOGY 
STUDY DESIGN: 
Prospective observational study. 
SOURCE OF STUDY: 
Cardiology ICCU ward, Government Rajaji Hospital, Madurai. 
SAMPLE SIZE : 
 80 patients with acute ST elevation myocardial infarction, 
irrespective of the diabetic status. 
DURATION OF STUDY  
One year (September 2010 –August 2011) 
STUDY POPULATION: 
INCLUSION CRITERIA: 
All acute myocardial infarction patients with 
 Chest pain lasting for more than 20 minutes. 
 Characteristic changes of ST elevation of 1mm or more in two or 
more contiguous leads or new onset left bundle branch block. 
  
 Elevated creatinine kinase MB levels >2 times the upper limit of 
normal. 
 Age > 40 yrs. 
 Both males and females. 
 Presentation < 48 hrs. 
 Duration of stay in the hospital > 6 hours. 
EXCLUSION CRITERIA: 
 Time from the onset of symptoms to hospital admission > 48 hrs. 
 Patients who had received dextrose containing fluids prior to 
hospital admission. 
 Patients receiving drugs elevating blood glucose 
(eg:corticosteroids). 
 Post surgical or post traumatic (upto one month). 
 Prior h/o MI/CAD. 
 Known hypertension. 
 Smokers. 
 Patients with Chronic Kidney Disease /Chronic Liver Disease. 
 Psychiatric patients. 
  
STUDY END POINTS AND DEFINITIONS: 
 The primary objective of the study was to estimate the incidence 
of complications after acute MI (congestive cardiac failure, 
left ventricular failure, cardiogenic shock, arrhythmias, 
thromboembolism, pericarditis, ventricular septal rupture, 
papillary muscle rupture, aneurysm) and mortality, if any 
during the hospital stay. 
 Blood glucose is the random blood glucose measured at the time 
of hospital admission. 
 STEMI is defined as the presence of chest pain > 20 minutes and 
electrocardiogram with ST elevation of >1mm in 2 or more 
contiguous leads or new onset LBBB with elevation of CK-MB 
>2 times upper limit of normal. 
 Hyperglycemia was defined as a random blood sugar ≥ 200 mg/dl 
(American Association of Clinical Endocrinologists Guidelines -
AACE 2011). 
 Stress Hyperglycemia was defined as a random blood sugar ≥ 
200 mg/dl (American Association of Clinical 
  




 HbA1c levels ≥ 6.5 % was used to define diabetes in those who 
had no previous history of diabetes (AACE- 2011). 
 HbA1c levels > 6.5 % was taken as uncontrolled diabetes in those 
with a previous history of diabetes (AACE – 2011). 
INVESTIGATIONS : 
1) Biochemical investigations   
 Hemoglobin 
 Random blood glucose – measured by the glucose oxidase-
peroxidase method. 
 Serum creatine kinase MB – measured by NAC activated method 
(Method of Olive Modified by Rosalki and Szasz). 
 HbA1c 
This was measured by ion-exchange high-performance liquid 
chromatography (HPLC). This method is certified by the National 
Glycohemoglobin Standardization Program (NGSP) as traceable to the 
Diabetes Control and Compliance Trial (DCCT) reference method. The 
  
method is fully automated, thus resulting in excellent precision, with 
typical inter-assay variation less than 4%. 
 Fasting lipid profile 
2) 12 Lead electrocardiography 
3)  2 -D Echocardiography  
STATISTICAL ANALYSIS : 
     The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done using 
Epidemiological Information Package (EPI 2010) developed by 
Centre for Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, 
standard deviations, chi square and 
 
'p'  values were calculated. Kruskul 
Wallis chi-square  test was used to test the significance of difference 
between quantitative variables and Yate‟s chi square test for qualitative 
variables. A 'p' value less than 0.05 is taken to denote significant 
relationship. 




In this study, there is no risk to the participant health, no 
procedure distressing to the participant was undertaken and there was no 
financial payment involved to the participant. A formal ethical 
committee approval was obtained and patients‟ oral, informed consent 















Age distribution of subjects in the diabetic and non diabetic group 
Age group Diabetic group Non – diabetic 
group 
No % No % 
41 -  50 years 6 18.8 10 20.8 
51 – 60 years 17 53.0 19 39.6 
61 – 70 years 6 18.8 14 29.2 
> 70 years 3 9.4 5 10.4 
Total 32 100 48 100 
Range 40 – 85 years 45 – 80 years 
Mean 58.7 years 59.4 years 
SD 9.1 years 8.8 years 
       
Persons aged above 40 years  were included in the study. Diabetic 
group had an age of 58.7 + 9.1 years and non diabetic group 59.4 + 8.8 





Table 2  
Sex distribution 
Sex Diabetic group Non – diabetic 
group 
No % No % 
Male 23 71.9 39 81.2 
Female 9 28.1 9 18.8 
Total 32 100 48 100 
         
           71.9% of the Diabetic and 81.2 % of the non diabetic  were males. 
There was no statistically significant difference in the sex composition 










Killip‟s class at admission of diabetic and non diabetic subjects 
Killip class Diabetic group Non – diabetic 
group 
No % No % 
I 23 71.9 34 70.9 
II 5 15.5 5 10.4 
III 2 6.25 5 10.4 
IV 2 6.25 4 8.3 
Total 32 100 48 100 
          
        Majority of cases included in both the Groups (71.9% and 70.9%) 









Table 4  
Admission blood sugar of diabetics and non diabetics 
Blood sugar 
(mg / dl) 
Diabetic group Non – diabetic 
group 
No % No % 
(≤200mg/dl) 15 46.9 43 89.6 
(>200mg/dl) 17 53.1 5 10.4 
Range 66 – 474 58 – 355 
Mean 229.8 131.3 




    Mean blood sugar of the diabetic group was 229.8 mg/dl and the non 
diabetic group was 131.3 mg/dl. This difference was statistically 







Table 5  
Lipid profile of diabetic and non diabetic subjects 
Lipid Diabetic group Non-diabetic 
group 
„p‟ 
Mean SD Mean SD 
Total Cholesterol 194.7 39.4 174.3 29.8 0.0021 
Significant 
TGL 195.6 35.7 173.3 29.8 0.0004 
Significant 
LDL 114.2 37.0 90.7 33.4 0.002 
Significant 
HDL 48.2 8.8 44.4 8.8 0.0426 
Significant 
VLDL 39.8 4.8 42.0 6.0 0.306 
Not Significant 
 
      Mean Lipid  values of the diabetic group ( except VLDL) were 





Table 6  
Relationship between blood sugar values and LVEF 
 
Blood sugar 






 > 40% 
LVEF 
< 40% 
No. % No. % No. % No. % 
Controlled 
( < 200mg/dl) 
13 86.7 2 13.3 31 74.4 12 25.6 
Not controlled 
( > 200 mg./dl) 
1 5.9 16 94.1 1 20 4 80 












There exists significant negative correlation between blood sugar 





Table 7  









( < 40%) 
Normal 
( > 40%) 
Abnormal 
( < 40%) 
No No No No 
≤ 6.5 % 5 - 32 5 













There exists significant negative correlation between HbA1C 






Table 8 :  Left ventricular ejection fraction 
 
Groups 
L V E F % 
Normal Abnormal Mean / SD 
No. % No. % 
A) Group 1 
(Uncontrolled Diabetes )(27) 
9 33.3 18 66.7 39.9 +  10.2 
B )Group 2 
( Controlled Diabetes )(5) 
5 100 - - 49.8 +  5.9 
C) Group 3 
(Stress Hyperglycemia)(2) 
- - 2 100 35.5 +  2.1 
D)Group 4 
( Undiagnosed  Diabetes)(9) 
- - 9 100 33.1 +  3 
E) Group 5  
(Normal cases) (37) 




Subjects with undiagnosed diabetes, stress hyperglycemia and 
uncontrolled diabetes had lower left ventricular injection fraction in that 




Table 9   





No % No % 
A) Group1 
(Uncontrolled Diabetes) (27) 
19 70.4 8 29.6 
B ) Group 2 
(Controlled Diabetes) (5) 
1 20 4 80 
C)Group 3 
(Stress Hyperglycemia) (2) 
2 100 - - 
D) Group 4 
(Undiagnosed  Diabetes) (9) 
6 66.7 3 33.3 
E)Group 5 
( Normal cases) (37) 
3 8.1 34 91.9 
 
The incidence of complications were found to be higher in 
subjects with stress hyperglycemia, uncontrolled diabetes and 




















    In our study, we included 80 cases of myocardial infarction, who 
had presented within 48 hours of onset of symptoms, irrespective of 
diabetic status and who satisfied the inclusion criteria. The patient‟s 
history was taken and physical examination findings were noted. At 
admission, patient‟s blood glucose values, electrocardiogram, cardiac 
enzymes and HbA1c were done. Fasting lipid profile and 
echocardiography were done during hospital stay. The patients were 
followed up during the hospital stay and in-hospital complications were 
noted. 
     A comparative analysis of those with a previous history of 
diabetes and those without, was done initially. The diabetic group had 
an age distribution of 58.7±9.1 years and the non diabetic group 
59.4±8.8 years. 71.9 % of the diabetics and 81.2 % of the non diabetics 
were males. There was no significant difference in the age or sex 
composition between the groups. Majority of cases included in both 
groups(71.9 % of diabetics and 79.8 % of non diabetics ) had a Killip‟s 
score of I. The mean blood sugar of the diabetic group was 229.8 mg/dl 
and the non diabetic group was 131.3 mg/dl. The difference was 
statistically significant. 
  
The mean HbA1c  of the diabetic group was 9.8 % and that of the 
non diabetic group was 6.57 %.This difference was statistically 
different. This is in accordance with a study by Tenerz et al  that showed 
that  patients with a history of diabetes, had higher mean hemoglobin 
A1c values than those with newly diagnosed diabetes, and patients with 
newly diagnosed diabetes had higher mean hemoglobin  A1c values than 
those without diabetes
30
.The diabetics were also found to have more 
deranged lipid levels as compared to the non diabetics. 
     The 80 patients included in this study were further stratified into 
five groups,based on previous history of diabetes, blood glucose levels 
at admission and HbA1c levels (American Association of Clinical 
Endocrinologists Guidelines 2011 ). 
Group 1  (uncontrolled diabetes) 
Previous history of diabetes with HbA1c > 6.5 %. 
 
Group 2  (controlled diabetes) 
  Previous history of diabetes with HbA1c ≤ 6.5 %. 
 
Group 3  (Stress hyperglycemia) :   
No previous history of diabetes, random blood glucose at 
admission ≥ 200 mg/dl and HbA1c<6.5 %. 
 
Group 4 (Undiagnosed diabetes) 
No previous history of diabetes,random blood glucose ≥ 200 
mg/dl and HbA1c ≥ 6.5%. 
Group 5  (Non diabetic) 
  No previous history of diabetes,random blood glucose < 
200 mg/dl and HbA1c < 6.5 %. 
  
There were 27 subjects under group 1 (uncontrolled diabetes) of 
which 70.4 % had complications during hospital stay and 66.7 % had an 
LVEF ≤ 40 %. 
Among the 5 patients in group 2 (controlled diabetes), only 1 
developed complication during hospital stay and all had an LVEF 
>40%. 
In group 3 (stress hyperglycemia),both patients developed 
complications and had an LVEF ≤ 40 %. 
There were 9 subjects in group 4 (undiagnosed diabetes),out of 
which 66.7 % developed complications and all had an LVEF ≤ 40 %. 
Group 5 included 37 patients, out of which only 8.1 % developed 
complications and only 13.5 % had an LVEF ≤ 40 %. 
It was noted from this study that the in hospital complication rate 
was higher in the uncontrolled diabetes group ,the newly diagnosed 
diabetic group and the stress hyperglycemia group. This is in 
concordance with the study by Nazneem et al.,which showed that 
patients known to have diabetes and those with hyperglycemia without a 
history of diabetes had a worse outcome after myocardial 
infarction
8
.This may be attributed to the fact that those patients with no 
  
prior history of diabetes had the lowest rates of exposure to 
cardiovascular disease modifying drugs like aspirin, statins, angiotensin 
converting enzyme inhibitors and beta blockers. 
     Our study showed that those with uncontrolled diabetes and the 
newly diagnosed diabetics, who had a higher incidence of complications  
had higher HbA1c levels and higher admission blood glucose values. 
These two groups also had lower left ventricular ejection fractions.  The 
contribution of stress hyperglycemia in these groups cannot be 
determined because previous records of blood glucose levels were not  
available.   
While hyperglycemia is a marker of post AMI stress, insulin 
resistance is related to the intensity of the stress.  A chronic pre-existing 
abnormal glycometabolic state inevitably affects the degree of metabolic 
response to stress, hence higher blood glucose levels are found during 
stress in patients with previously known IGT
31
. This could explain the 
occurrence of high blood glucose levels and also higher HbA1c levels in 
this subset of patients.  A study done by Mahmut et al. have shown 
similar results that both acute and chronic glycometabolic states are an 
indicator of prognosis after AMI. 
 
  
The stress hyperglycemia group had lower left ventricular 
ejection fraction and increased incidence of complications compared to 
the non diabetic subjects. 
Several hypothesis have been put forward to explain the relation 
between stress hyperglycemia and poor outcome.  Stress hyperglycemia 
may be a marker of extensive myocardial damage, reflecting a surge of 
stress hormones such as catecholamines and cortisol that produce or 
augment an insulin resistant state.
32,33.
  Relative insulin deficiency and 
excess catecholamines reduce glucose uptake by the ischemic 
myocardium and promote lipolysis and increased circulating free fatty 
acids.  The latter inhibit glucose oxidation (the “glucose-fatty cid 
cycle”) and are toxic to ischemic myocardium, resulting in increased 
membrane damage, arrhythmias, and reduced contractility. 
34,35,36,37
. 
Alternatively, elevated blood glucose levels per se adversely 
affect outcome through the cumulative effects of several mechanisms, 





hypercoagulability, and impaired fibrinolysis
40
. Admission 
hyperglycemia may not only be the cause of more severe myocardial 
damage but also its consequence.  Large infarcts are more likely to 
cause catecholamine release, which affect acid and glucose homeostasis.  
  
But conclusions on the effect of stress hyperglycemia on 
prognosis after myocardial infarction cannot be drawn in our study 
because of the relatively small number of patients in this group. 
However, the results of our study clearly show that long term 
blood glucose control, as reflected by the HbA1c levels, have an 
important role in predicting the prognosis after acute ST elevation MI. 
Many of the studies examining acute MI patients in the 
hyperglycemic state did not measure HbA1c, and hence, they were 
not able to demonstrate pre-existing diabetes. Undiagnosed diabetes 
was found in 4.3% of patients in one study, contributing to 
approximately 10% of mortality
41
. Levetan et al
42
 also 
demonstrated that one-third of hospitalized patients had at least one 
glucose level reading higher than 200 mg/dl. In the presence of 
high glucose levels, stress hyperglycemia should be differentiated 
from diabetes. The admission glucose level can not be used to 
predict the prognosis in diabetic patients. Because admission blood 
glucose levels had begun to lose its significance in predicting the 
prognosis of patients with acute MI in diabetics, recently focus has 
been on HbA1c level as a prognostic marker in these patients. 
  
Therefore, HbA1c can be used as a tool in these settings to 
identify patients with pre existing diabetes and to differentiate 
between uncontrolled diabetes and stress hyperglycemia and also 














LIMITATIONS OF THE STUDY 
1) Our study included only a limited number of patients and there 
was an unequal distribution of cases among the different 
groups as HbA1c could not be done as a routine investigation 
in all patients with acute MI in our hospital. 
2) The diagnosis of pre existing diabetes could not be confirmed 
by the oral glucose tolerance test after discharge from hospital. 
3) Mortality and complication rates are also influenced by factors 
such as the presence or absence of recanalization, infarct sites, 
the time from disease onset to treatment, Killip‟s classification 
at admission, ST segment elevation resolution and left 
ventricular function. 
4) Since we included only those patients who survived the first 6 
hours of hospital stay for feasibility of acquiring the necessary 
investigations ,the actual mortality rates cannot be established 
by our study. 
5) Despite these limitations,our results clearly demonstrated that 
both acute and chronic glycometabolic states are indicators of 
prognosis after acute MI.  
  
CONCLUSIONS 
The following conclusions were made after the completion of the study: 
 Subjects with uncontrolled diabetes had a higher incidence of 
complications during hospital stay and a lower left ventricular 
ejection fraction. 
 Subjects with newly diagnosed diabetes had higher admission 
blood glucose levels and HbA1c which correlated with a higher 
incidence of complications during hospital stay and a lower left 
ventricular ejection fraction. 
 There was a significant negative correlation between HbA1c 
levels and left ventricular ejection fraction. 
 There was a significant negative correlation between admission 
blood glucose levels and left ventricular ejection fraction. 
 Our results suggest that both acute and chronic hyperglycemia are 
independent predictors of adverse outcome after acute ST 
elevation myocardial infarction. Hence, measurement of both 
blood glucose as well as HbA1c enables identification of these 
high risk groups for aggressive management. 
  
SUMMARY 
A prospective, observational study was conducted in 80 patients 
with acute ST elevation myocardial infarction, irrespective of their 
diabetic status, in Government Rajaji Hospital, Madurai for a period of 
one year. The aim of the study was to investigate the prognostic 
importance of admission blood glucose and glycosylated hemoglobin 
levels in patients with acute ST elevation myocardial infarction. The 
results showed that  the in hospital complication rate was higher in the 
uncontrolled diabetes group ,the newly diagnosed diabetic group and the 
stress hyperglycemia group.  
Our study showed that those with uncontrolled diabetes and the 
newly diagnosed diabetics, who had a higher incidence of complications  
had higher HbA1c levels and higher admission blood glucose values. 
These two groups also had lower left ventricular ejection fractions. The 
stress hyperglycemia group had lower left ventricular ejection fraction 
and increased incidence of complications compared to the non diabetic 
subjects.  There was a significant negative correlation between HbA1c 
levels and left ventricular ejection fraction. There was a significant 
negative correlation between admission blood glucose levels and left 
ventricular ejection fraction. Our results suggest that both acute and 
  
chronic hyperglycemia are independent predictors of adverse outcome 
after acute ST elevation myocardial infarction. Hence, measurement of 
both blood glucose as well as HbA1c enables identification of these high 
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                                             PROFORMA 
Name:                  Age:            Sex: 
Date of admission: 




 Ischaemic heart disease 
 Surgery 
Personal history: 
 Smoking (if yes,no. of pack yrs.) 
 Tobacco use 
 
Killip‟s Class : 
INVESTIGATIONS: 
 Admission Blood Glucose 
 Creatine kinase MB 
 Lipid Profile 
Total cholesterol - 
Triglycerides        - 
LDL                        - 
VLDL                      - 








Rate              Rhythm          QRS axis             PR interval 
QRS interval             QTc interval         
ST elevation 
T wave changes 
Pathological Q waves 
Interpretation  
 Echocardiography  




Clot / aneurysm 
Pericardial effusion 
Thrombolysis – done / not done 
In hospital complications: 
 CCF/LVF 




 Rupture of interventricular septum 
 Rupture of papillary muscle 
 Aneurysm 
 Any other 






















































































1 tamilselvi 46 f E No III 104 190 186 103 41 44 6.3% 55 t 
2 sukumar 65 m E No III 87 178 192 78 44 38 6.3% 57 t 
3 ganapathy 65 m E No II 63 162 184 92 42 40 5.7% 71 t 
4 samuel 48 m E No I 63 186 190 76 38 38 5.0% 72 t 
5 subbulakshmi 55 f E No I 151 188 174 78 42 40 6.3% 52 t 
6 sonai 50 m D No II 203 215 229 50 45 40 7.6% 38 grII MR / t 
7 murugesan 47 m E No I 162 209 216 71 44 46 5.3% 54 t 
8 mohammed 57 m E No I 58 155 138 98 27 40 5.2% 58 t 
9 ramar 70 m B Yes III 146 187 108 127 22 38 5.6% 45 t 
10 mayandi 50 m E No I 103 178 168 103 33 42 5.8% 44 nt 
11 rathinam 70 m D No IV 203 216 174 98 46 32 14.2% 32 t 
12 mahadevan 52 m A Yes I 202 339 210 255 42 42 10.3% 38 t 
13 satasivam 76 m E No I 128 221 148 190 40 42 6.4% 35 t 
14 radhakrishnan 48 m A Yes I 320 205 224 174 38 41 9.6% 31 large lv clot / nt / chb 
15 manoharan 50 m E No I 130 162 171 105 45 38 5.8% 45 t 
16 karungan 58 m E No I 83 174 162 128 40 40 6.4% 51 nt 
17 sonai 57 m E No III 171 118 170 42 34 42 6.3% 42 MR grI / nt 
18 balusamy 60 m D No II 201 120 150 54 30 42 8.5% 31 large lv clot / t 
19 kannan 56 m D No I 255 181 121 117 24 40 9.8% 34 large lv clot / nt / chb 
20 soundaravalli 60 f A Yes I 285 211 148 106 38 37 8.8% 50 t 






22 vadivel 56 m A Yes I 379 208 217 87 42 39 8.5% 47 lv apical clot / t 
23 murugesan 52 m E No I 90 179 182 91 36 40 6.0% 49 t 
24 palaniammal 69 f A Yes II 274 205 176 88 42 45 8.5% 35 t 
25 anjagnanam 55 m E No I   149 196 180 74 44 48 6.2% 61 t 
26 kalaiselvan 56 m E No II 104 178 182 80 44 46 6.3% 30 large lv clot / t 
27 devadoss 53 m  E No I 87 180 174 89 46 40 6.4% 53 vt / nt 
28 karupaiah 67 m D No I 204 184 176 93 44 46 6.7% 32 MR I / t 
29 asiya 55 f E No I 82 188 180 89 40 46 6.2% 52 MR I / t 
30 ayyam perumal 57 m E No I 87 178 176 77 43 48 6.5% 55 t 
31 gopal 65 m A Yes I 286 187 180 120 50 42 12.8% 38 MR II /t 
32 narayanan 62 m E No I 120 165 168 112 45 46 6.0% 41 t 
33 balakrishnan 45 m E No I 130 229 260 138 52 39 5.8% 69 t 
34 gurusamy 65 m B Yes II 191 203 224 143 56 39 5.9% 54 t 
35 karuppaiah 60 m D No I 208 165 240 39 58 68 6.7% 31 t 
36 sahul ahmed 74 m A Yes I 309 122 220 73 44 35 8.2% 30 
MR,LV apical clot / 
t/CCF/cpa(rec) 
37 chinnaiya 68 m E No I 171 154 187 77 45 48 5.8% 65 MR I / t 
38 velammal 45 f A Yes I 341 224 225 134 49 41 14.7% 27 MR I / transient CHB / t 
39 rakkaiyee 70 f E No I 121 167 174 67 46 39 6.3% 62 nt 
40 chinnaponnu 55 f A Yes I 207 215 189 86 46 42 6.6% 52 t 
41 palsamy 61 m E No II 126 198 167 92 48 42 5.4% 67 t 
42 shanmuganathan 57 m A Yes I 474 227 254 132 52 41 13.9% 33 grII MR / t 
  
43 valliamal 60 f A Yes I 431 161 249 71 49 41 11.7% 31 
MR,LV apical clot / 
t/CCF/cpa(rec) 
44 iyavu 75 m E No IV 118 136 185 58 37 41 6.4% 33 CHB,HIE / t 
45 karupayee 65 f C No I 210 187 197 79 52 46 6.0% 37 CHB / nt 
46 muthusamy 60 m A Yes II 231 237 201 150 40 42 10.1% 35 large lv clot / nt / chb 
47 gajendran 55 m A Yes I 385 221 207 137 41 43 10.0% 47 vt / nt 
48 ramkumar 45 m C No I 205 187 165 156 54 48 5.5% 34 
trivial mr/ar / nt / vt/c 
shock 
49 rakamal 55 f A Yes IV 259 202 280 104 56 42 13.5% 41 
MR,LV apical clot / 
t/CCF/cpa(rec)  
50 madurasamy 72 m D No I 226 132 181 60 36 36 14.2% 30 MR III / nt 
51 sathyamurthy 73 m A Yes I 225 177 168 76 49 45 6.7% 73 t 
52 dhanam 55 f E No I 90 250 179 173 36 41 6.1% 42 MR I /t 
53 sevugan 46 m A Yes I 322 212 206 98 56 43 11.6% 28 grII MR / t 
54 balu 48 m A Yes I 301 199 187 131 45 46 13.1% 35 grII MR  /t  
55 ganesan 58 m A Yes I 402 187 185 92 56 44 11.9% 38 
grI MR,severe LV / 
t/death(cpa) 
56 kumaran 49 m A Yes IV 389 188 176 89 54 40 10.6% 44 CHB / nt 
57 durai 58 m A Yes I 305 196 190 90 56 44 13.3% 36 grII MR / t 
58 mariammal 56 f A Yes I 209 187 192 78 55 41 8.9% 36 
MR,LV apical clot / 
t/CCF/cpa(rec) 
59 iyapan 56 m E No i 66 167 145 82 50 44 6.4% 40 t 
60 ramamoorthy 47 m E No I 60 157 160 67 45 40 6.5% 34 large lv clot / t 
61 subbaiah 74 m D No I 206 167 154 87 56 48 6.9% 38 trivial mr/ar / t 
62 joseph selvaraj 54 m A Yes I 366 189 198 135 48 40 8.9% 59 t 
63 pitchai 47 m B Yes I 87 198 201 143 62 42 6.1% 50 t 
64 thirumal 58 m E No III 69 160 146 88 45 40 5.8% 76 t 
65 santhanalakshmi 66 f E No I 84 178 180 114 56 48 5.7% 65 grI MR / t 
66 muthulakshmi 60 f E No IV 121 190 186 146 60 43 5.2% 74 nt  
  
67 periyakaruppan 65 m E No I 136 114 120 74 44 42 5.9% 63 t/transient CHB 
68 gopal 68 m E No IV 166 150 222 44 76 40 5.4% 72 vt / nt 
69 karupasamy 65 m E No I 99 153 136 72 46 40 6.4% 53 t 
70 irudayasamy 68 m B Yes I 96 189 199 113 59 40 6.1% 57 t 
71 subramany 85 m A Yes II 251 167 189 121 62 43 7.0% 45 T 
72 iyyamal 64 f A Yes I 271 111 225 67 45 26 11.7% 31 MRI / transient CHB / t 
73 velandi 50 m D No I 201 144 198 64 54 48 7.0% 32 trivial mr/ar / t 
74 vallavan 65 m E No I 119 138 174 64 49 35 5.9% 60 t 
75 ramu 55 m E No I 92 126 110 69 42 32 5.5% 71 t 
76 meenal 60 m E No I 63 227 124 160 42 34 6.2% 53 t 
77 kathiravan 51 m B Yes II 137 170 128 102 42 26 6.3% 43 
grII MR,LV apical clot / 
recurrent vt / nt 
78 pushpam 80 f E No III 126 190 136 94 45 28 6.4% 54 t 
79 shanmugam 60 m A Yes I 326 117 195 132 40 33 8.4% 38 MR I / transient CHB / t 





t  - Thrombolysed                                    nt  -  not thrombolysed             LV Clot  -  Left ventricular clot 
   
CCF - Congestive cardiac failure           CHB - Complete heart block           MR  - Mitral Regurgitation 
   
HIE  - Hypoxic Ischemic Encephalopathy   AR -  Aortic Regurgitation          CPA - Cardio Pulmonary  
   
VT  - Ventricular Tachycardia                     LVF - Left ventricular failure        Arrest 
   
A  Uncontrolled Diabetes 
   
B Controlled Diabetes 
   
C Stress hyperglycemia 
   
D Undiagnosed Diabetes 
   
E Non Diabetic 
 
  
 
